Navigation Links
BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation

BOSTON Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center (BIDMC) and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation (PCF). The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

Patnaik's research focuses on the relationship between diet-induced obesity /associated metabolic abnormalities and prostate cancer. With the PCF funding, he will investigate the molecular mechanisms that link the metabolic abnormalities of obesity to poor outcomes in prostate cancer patients.

"Hormones, such as insulin, are increased in obese patients and are known to drive the progression and survival of prostate cancer cells," Patnaik explains. "Recent epidemiological studies have shown that men who are treated with metformin, a medication prescribed for Type 2 diabetes, have a reduced risk of prostate cancer." Patnaik will evaluate the anti-cancer mechanism and efficacy of metformin and related medications to prolong overall survival of patients with advanced prostate cancer.

"Obesity is strongly associated with poor prostate cancer prognosis," notes Lewis Cantley, PhD, Patnaik's postdoctoral research mentor and Director of BIDMC's Cancer Center and William Bosworth Castle Professor of Medicine at Harvard Medical School. "Dr. Patnaik's investigations promise to provide us with a better understanding of the molecular events that drive obesity-induced cancers, and provide a rationale for a new metabolic treatment strategy for advanced prostate-cancer patients."

Patnaik will utilize a "co-clinical trial paradigm" to identify novel targeted therapies for advanced prostate cancer patients. In this way he will assess the responses of genetically engineered mouse models to specific cancer drugs, and then use this information to stratify patients into specific treatment arms, based on patients' cancer mutations and their individual metabolic profiles.


Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center

Related medicine news :

1. Researchers suggest new paradigm for breast cancer screening
2. Of lice and man: Researchers sequence human body louse genome
3. AcademyHealth honors leading health services researchers
4. UCLA researchers, US military collaborate to open center for traumatic brain injury
5. Texas A&M researcher explains how embryo fights retroviral infection
6. UC San Diego researcher awarded $5.3 million for breast cancer survivorship study
7. UCSD researchers receive $2.5 million in new stem cell grants
8. Researchers find key to getting estrogens benefits without cancer risk
9. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
10. WSU researchers find mothers of children with autism pay price in workplace
11. Free Resources from EBSCO Publishing Providing Useful Information to Researchers
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: